Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406471 · ClinicalTrials.gov registry record · Phase 1
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
A Phase 1 study of Ischemic Central Retinal Vein Occlusion, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00406471: Completed Phase 1 study of Ischemic Central Retinal Vein Occlusion, sponsored by Greater Houston Retina Research.
NCT00406471 is a Phase 1 study of Ischemic Central Retinal Vein Occlusion that has completed, run by Greater Houston Retina Research. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00406471, a Phase 1 study of Ischemic Central Retinal Vein Occlusion, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
Conditions Studied
Interventions
- DRUG Ranibizumab (Lucentis)
Study Locations (1)
Texas
- Vitreoretinal Consultants - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
What the finished NCT00406471 record still lists
NCT00406471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Ischemic Central Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab (Lucentis) is the first listed.
NCT00406471 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00406471 about?
NCT00406471 is a clinical study titled "Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion". The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
What is the current status of trial NCT00406471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-05. Estimated completion is 2011-01.
What conditions does trial NCT00406471 study?
This clinical trial studies the following conditions: Ischemic Central Retinal Vein Occlusion.
What interventions are being tested in trial NCT00406471?
The interventions under investigation include: Ranibizumab (Lucentis) (DRUG).
Who is sponsoring clinical trial NCT00406471?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406471 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00406471's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia